FDA Moving Forward On Primary Bacteremia Indication
Executive Summary
FDA will continue work on defining an indication for primary bacteremia due to Staph aureus (PBSA) after the agency found support for the claim from the Anti-Infective Drugs Advisory Committee
You may also be interested in...
Cubicin Resistance Should Be Closely Monitored In Bacteremia Patients
Labeling regarding use of Cubist's anti-infective Cubicin in Staphylococcus aureus patients should include a recommendation for close monitoring for development of resistance, members of FDA's Anti-Infective Drugs Advisory Committee said March 6
Cubicin Resistance Should Be Closely Monitored In Bacteremia Patients
Labeling regarding use of Cubist's anti-infective Cubicin in Staphylococcus aureus patients should include a recommendation for close monitoring for development of resistance, members of FDA's Anti-Infective Drugs Advisory Committee said March 6
Cubist Boosts Cubicin Sales Reps, Will Detail 80% Of Vancomycin Prescribers
Cubist will increase its Cubicin (daptomycin) sales force by one third in the first quarter, bringing the total to 100 reps, CEO Michael Bonney said